AU2019341723C1 - Purified capsular polysaccharides of Streptococcus pneumoniae - Google Patents

Purified capsular polysaccharides of Streptococcus pneumoniae Download PDF

Info

Publication number
AU2019341723C1
AU2019341723C1 AU2019341723A AU2019341723A AU2019341723C1 AU 2019341723 C1 AU2019341723 C1 AU 2019341723C1 AU 2019341723 A AU2019341723 A AU 2019341723A AU 2019341723 A AU2019341723 A AU 2019341723A AU 2019341723 C1 AU2019341723 C1 AU 2019341723C1
Authority
AU
Australia
Prior art keywords
polysaccharide
kda
protein
psaa
serotype
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019341723A
Other languages
English (en)
Other versions
AU2019341723B2 (en
AU2019341723A1 (en
Inventor
Rajendar Burki
Mahima DATLA
Vivek Babu KANDIMALLA
Narender Dev MANTENA
Ramesh Venkat Matur
Veerapandu SANGAREDDY
Rajan Sriraman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biological E Ltd
Original Assignee
Biological E Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69886702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2019341723(C1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biological E Ltd filed Critical Biological E Ltd
Publication of AU2019341723A1 publication Critical patent/AU2019341723A1/en
Publication of AU2019341723B2 publication Critical patent/AU2019341723B2/en
Application granted granted Critical
Publication of AU2019341723C1 publication Critical patent/AU2019341723C1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08H—DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
    • C08H1/00—Macromolecular products derived from proteins
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L89/00—Compositions of proteins; Compositions of derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Sustainable Development (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
AU2019341723A 2018-09-23 2019-09-23 Purified capsular polysaccharides of Streptococcus pneumoniae Active AU2019341723C1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN201841031654 2018-09-23
IN201841031653 2018-09-23
IN201841031653 2018-09-23
IN201841031654 2018-09-23
PCT/IB2019/058036 WO2020058963A1 (en) 2018-09-23 2019-09-23 Purified capsular polysaccharides of streptococcus pneumoniae

Publications (3)

Publication Number Publication Date
AU2019341723A1 AU2019341723A1 (en) 2021-05-20
AU2019341723B2 AU2019341723B2 (en) 2024-03-21
AU2019341723C1 true AU2019341723C1 (en) 2026-01-22

Family

ID=69886702

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019341723A Active AU2019341723C1 (en) 2018-09-23 2019-09-23 Purified capsular polysaccharides of Streptococcus pneumoniae

Country Status (12)

Country Link
US (2) US12048739B2 (enExample)
EP (1) EP3852795A4 (enExample)
JP (2) JP2022513562A (enExample)
KR (1) KR102879391B1 (enExample)
CN (1) CN113164581A (enExample)
AU (1) AU2019341723C1 (enExample)
BR (1) BR112021005425A2 (enExample)
MX (1) MX2021003358A (enExample)
MY (1) MY206212A (enExample)
PH (1) PH12021550539A1 (enExample)
WO (1) WO2020058963A1 (enExample)
ZA (1) ZA202101663B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
ES3058336T3 (es) 2017-12-06 2026-03-10 Merck Sharp & Dohme Llc Composiciones que comprenden conjugados polisacárido-proteína de Streptococcus pneumoniae y métodos de uso de los mismos
CR20210333A (es) 2018-12-19 2021-08-18 Merck Sharp & Dohme Composiciones que comprenden conjugados de polisacárido de streptococcus pneumoniae con proteína y sus métodos de uso
KR20220017996A (ko) * 2019-06-05 2022-02-14 머크 샤프 앤드 돔 코포레이션 면역원성 혈청형 35b 폐렴구균 폴리사카라이드-단백질 접합체 및 그를 제조하기 위한 접합 방법
MY207887A (en) * 2020-05-01 2025-03-26 Sinocelltech Ltd Method for improving immunogenicity of protein/peptide antigen
WO2022084852A1 (en) * 2020-10-22 2022-04-28 Pfizer Inc. Methods for purifying bacterial polysaccharides
CA3200602A1 (en) * 2020-11-04 2022-05-12 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
EP4288106A4 (en) * 2021-02-04 2025-06-04 Merck Sharp & Dohme LLC Lipid DNANOparticle adjuvant composition for pneumococcal conjugate vaccines
WO2024062494A1 (en) * 2022-09-19 2024-03-28 Biological E Limited Method for the purification of capsular polysaccharides
CN117512031B (zh) * 2023-10-16 2024-06-25 江苏金迪克生物技术股份有限公司 一种肺炎球菌荚膜多糖的纯化方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160324949A1 (en) * 2014-01-21 2016-11-10 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
WO2017067962A1 (en) * 2015-10-21 2017-04-27 Glaxosmithkline Biologicals S.A. Vaccine
WO2017173415A2 (en) * 2016-03-31 2017-10-05 Liffey Biotech Limited Saccharide-polypeptide conjugate compositions and methods of use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0027888B1 (en) 1979-09-21 1986-04-16 Hitachi, Ltd. Semiconductor switch
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
ES2204900T3 (es) 1992-02-11 2004-05-01 Henry M. Jackson Foundation For The Advancement Of Military Medicine Estructura inmuinogena de doble vector.
ATE280235T1 (de) 1993-03-05 2004-11-15 Wyeth Corp Plasmid zur herstellung von crm-protein und diphtherie-toxin
WO1995008348A1 (en) 1993-09-22 1995-03-30 Henry M. Jackson Foundation For The Advancement Of Military Medicine Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
NZ304715A (en) 1995-03-22 1999-07-29 Jackson H M Found Military Med Production of immunogenic constructs using organic cyanylating reagents to activate carbohydrates and then coupling the carbohydrate to a protein, peptide or hapten
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
JP6502262B2 (ja) * 2012-12-20 2019-04-17 ファイザー・インク 糖複合化方法
CN110859957B (zh) 2014-01-21 2024-04-12 辉瑞公司 包含缀合荚膜糖抗原的免疫原性组合物及其用途
CA2968491C (en) 2014-11-20 2023-09-26 Biological E Limited Codon optimized polynucleotide for high level expression of crm197
EP3374376B1 (en) 2015-11-09 2020-03-18 Biological E Limited Industrially scalable process for recovering biologically active recombinant carrier proteins
NZ752348A (en) * 2016-09-30 2022-11-25 Biological E Ltd Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates
CN110366428B (zh) * 2016-12-30 2024-05-17 Vaxcyte公司 具有非天然氨基酸的多肽-抗原缀合物
JP7680185B2 (ja) * 2017-02-24 2025-05-20 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎連鎖球菌多糖－タンパク質コンジュゲートの免疫原性の増強
SMT202200356T1 (it) 2017-04-22 2022-11-18 Biological E Ltd Un metodo migliorato per produzione ad alto livello di crm
WO2019050814A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. ANTI-PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC CONJUGATES POLYSACCHARIDE-PROTEIN CARRIER
MX394767B (es) 2017-09-07 2025-03-24 Merck Sharp & Dohme Llc Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.
CN111093650B (zh) 2017-09-07 2024-03-01 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160324949A1 (en) * 2014-01-21 2016-11-10 Pfizer Inc. Streptococcus pneumoniae capsular polysaccharides and conjugates thereof
WO2017067962A1 (en) * 2015-10-21 2017-04-27 Glaxosmithkline Biologicals S.A. Vaccine
WO2017173415A2 (en) * 2016-03-31 2017-10-05 Liffey Biotech Limited Saccharide-polypeptide conjugate compositions and methods of use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ALJANABY, JOURNAL OF BABYLON UNIVERSITY/PURE AND APPLIED SCIENCES, vol. 21, no. 5, 2013, pages 1648 - 1656 *
BEYNON ET AL., CAN. J.CHEM., vol. 73, 1995, pages 41 - 48 *
VENKATESWARAN P. S., STANTON N., AUSTRIAN R., THE JOURNAL OF INFECTIOUS DISEASES, vol. 147, no. 6, June 1983 (1983-06-01), pages 1041 - 1054, DOI: 10.1093/infdis/147.6.1041 *

Also Published As

Publication number Publication date
WO2020058963A1 (en) 2020-03-26
KR20210062669A (ko) 2021-05-31
BR112021005425A2 (pt) 2021-06-15
AU2019341723B2 (en) 2024-03-21
US20240325516A1 (en) 2024-10-03
EP3852795A4 (en) 2022-11-23
ZA202101663B (en) 2024-08-28
CN113164581A (zh) 2021-07-23
US20210346488A1 (en) 2021-11-11
MX2021003358A (es) 2021-05-27
KR102879391B1 (ko) 2025-10-30
US12465632B2 (en) 2025-11-11
JP2022513562A (ja) 2022-02-09
PH12021550539A1 (en) 2022-02-21
AU2019341723A1 (en) 2021-05-20
JP2024160305A (ja) 2024-11-13
US12048739B2 (en) 2024-07-30
MY206212A (en) 2024-12-04
EP3852795A1 (en) 2021-07-28

Similar Documents

Publication Publication Date Title
AU2019341723C1 (en) Purified capsular polysaccharides of Streptococcus pneumoniae
JP7403576B2 (ja) 多糖類－タンパク質コンジュゲートを含む多価肺炎球菌ワクチン組成物
JP7558944B2 (ja) 多価肺炎球菌多糖類－タンパク質コンジュゲートワクチン
WO2020157772A1 (en) Multivalent pneumococcal polysaccharide-protein conjugate vaccine compositions
US20230101892A1 (en) Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates
WO2020152706A1 (en) Multivalent pneumococcal conjugate vaccine compositions
OA20178A (en) Purified capsular polysaccharides of streptococcus pneumoniae.
EA048093B1 (ru) Очищенные капсульные полисахариды streptococcus pneumoniae
EA048146B1 (ru) Композиции поливалентной пневмококковой вакцины, содержащие конъюгаты полисахарид-белок
EA047156B1 (ru) Мультивалентная вакцина на основе конъюгата пневмококковый полисахарид-белок
OA20315A (en) Multivalent pneumococcal polysaccharide-protein conjugate vaccine.
HK40050226B (zh) 多价肺炎球菌多糖-蛋白缀合的疫苗
OA19223A (en) Multivalent pneumococcal vaccine compositions comprising polysaccharideprotein conjugates.
HK40050226A (en) Multivalent pneumococcal polysaccharide-protein conjugate vaccine
EA040051B1 (ru) Композиции поливалентной пневмококковой вакцины, содержащие конъюгаты полисахарид-белок

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 25 OCT 2024

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT FILED 25 OCT 2024

CH Opposition withdrawn

Opponent name: MERCK SHARP & DOHME LLC

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 19 AUG 2025, 11 JUN 2025

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 19 AUG 2025 AND 11 JUN 2025

FGA Letters patent sealed or granted (standard patent)